AUA 2021 Press Releases

Viewing 1-5 of 5 articles

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial

Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates

Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender

Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021